No content results match your keyword.
Content
You have successfully logged out.
Not registered yet?
No content results match your keyword.
Content
No product results match your keyword.
Products
Integrated Annual Report 2023
Our fiscal year 2023 marks the end of the first phase of our strategic framework, B. Braun—the next decade. Over the past three years, we have worked hard to make new technologies available to the health care sector. This is how we are creating tangible progress for our customers, and for improved patient care.
B. Braun is one of the world’s leading medical technology companies. As a true partner, we develop smart solutions and set standards to improve health care. We utilise the latest technology to enhance the benefits of our core medical products with other products, services and digital systems. Our integrated solutions aim to make medical treatment more innovative, more efficient and more sustainable.
Along with our strategy, we continued to grow our business in 2023, again in a demanding environment. B. Braun sales grew 6.5 percent at constant exchange rates. We maintained our long-term growth strategy and met our strategic target corridor of 5 to 7 percent. Sales in the reporting currency increased 3.0 percent to € 8.8 billion (previous year: € 8.5 billion). Profit before taxes improved 15.3 percent. This proves that we have the experience and skills to navigate through volatile times.
| 2022 | 2023 | Change in % | |
| Sales (in € million) | 8,499.8 | 8,755.0 | + 3.0 |
| EBITDA (in € million) | 997.2 | 1,019.4 | + 2.2 |
| Profit before taxes (in € million) | 178.7 | 206.0 | + 15.3 |
Employees (as of December 31) | 65,055 | 63,011 | - 3.1 |
Innovation is the driving force behind B. Braun’s success. We invested 1.2 billion euros in technology, production capacity, and research and development based on our long-term view. At our production sites, we utilise digital processes and work on our core medical products including investments in automation, robotics, sensor technology and predictive maintenance. In the reporting year, we invested 5.5 percent of our sales in research and development. These investments will strengthen our foundation as an independent, family-owned company.
Sustainability is one of our company values and is firmly embedded in our Group strategy. We understand that this means utilising the resources available to us in a way that is economically, ecologically, and socially responsible. This is why we make our business decisions with the generations of today and tomorrow in mind. We spent 2023 continuing to pursue our strategic focus, to gradually incorporate sustainability into all of our business models, processes, and management functions. Modern technologies and continuous improvement are key to successfully implementing sustainability across the company’s value chain.
With our committed employees, a clear set of values and the possibilities of new technologies, we are well positioned for the next phase of our strategy. Together, we continue to fulfill our vision to be a leading medical technology company that protects and improves the health of people around the world.
Register or login below to access your personalised account, with applications and content tailored specifically to you and your speciality.
